glp 1 agonist benefits EASD 2018: of GIP/GLP-1 receptor co-agonists in T2D The Benefits of GLP-1 Therapy:

338 adults were enrolled in total

Eli Lilly needed to design a molecule with the right balance of activity at both receptors

Real-world prescription data from Germany indicated that, among those switching between GLP-1 receptor agonists (exenatide twice daily, exenatide once weekly, dulaglutide once weekly, or liraglutide once daily), post-switch persistence rates were greater among those receiving dulaglutide once weekly compared with liraglutide once daily and exenatide twice daily (Figure 1) (57)

These properties make it an attractive target for treating hyperglycemia and obesity

Unlike traditional GLP-1 drugs, tirzepatide targets both GLP-1 and GIP receptors, unlocking superior weight-loss results compared to semaglutide (OZEMPIC, WEGOVY)

Glucagon-like peptide 1 (GLP-1) receptor agonists use during pregnancy: safety data from regulatory clinical trials